Pfizer has sued India’s Aurobindo Pharma over an alleged patent infringement of cholesterol lowering drug Lipitor.

Lipitor is one of the best selling medications in the US market, with annual sales of approximately $7bn, according to the US Food and Drug Administration.

Pfizer has patents over the drug until 2017 and has already sued a number of global generic firms over patent infringement, including Ranbaxy and Dr Reddy’s.

Aurobindo may opt for out-of-court settlement with Pfizer, which sued the Indian drugmaker on Monday.

Pfizer has filed the patent infringement case against Aurobindo in the district court of Delaware, US, following the filing of abbreviated new drug application by the Indian firm.

The global pharmaceutical company has urged the court to refrain Aurobindo from manufacturing and marketing of the drug before 8 January 2017, when Pfizer’s patents on the drug expires.